Virpax Pharmaceuticals, Inc. has formally withdrawn its request to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company had previously sought to expedite the process with a request filed on May 2, 2024, for the Registration Statement to be effective by May 2, 2024, at 5:00 p.m. Eastern Time. However, in a correspondence to the SEC dated May 3, 2024, Virpax's CEO Gerald Bruce indicated the company is no longer pursuing the accelerated effective date and has retracted the request. The correspondence was addressed to Daniel Crawford at the SEC's Division of Corporation Finance.

Virpax Pharmaceuticals, Inc. has formally withdrawn its request to accelerate the effective date of its Registration Statement on Form S-1, initially filed on April 18, 2024. The company had previously sought to expedite the process with a request filed on May 2, 2024, for the Registration Statement to be effective by May 2, 2024, at 5:00 p.m. Eastern Time. However, in a correspondence to the SEC dated May 3, 2024, Virpax's CEO Gerald Bruce indicated the company is no longer pursuing the accelerated effective date and has retracted the request. The correspondence was addressed to Daniel Crawford at the SEC's Division of Corporation Finance.